Comparison
6q Terminal Deletion Syndrome C4304514 vs 2 Hydroxyphenylacetic Aciduria C5937087
Clinical comparison between 6Q Terminal Deletion Syndrome and 2 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
2 Hydroxyphenylacetic Aciduria C5937087
A rare metabolic disorder where the body cannot properly process certain acids. It may cause neurological issues and is typically identified in infancy. Management involves diet modifications and supportive care.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
2 Hydroxyphenylacetic Aciduria C5937087
0-null
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
2 Hydroxyphenylacetic Aciduria C5937087
moderate
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
2 Hydroxyphenylacetic Aciduria C5937087
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
2 Hydroxyphenylacetic Aciduria C5937087
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 2-hydroxyphenylacetic-aciduria-C5937087 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 2 Hydroxyphenylacetic Aciduria C5937087 | Discriminating power |
|---|---|---|---|
| Developmental concerns | Developmental delay is described as a feature of the chromosomal deletion. | Neurological issues may occur, but a specific pattern is not established. | Moderate |
| Congenital physical features | Variable physical features may be present and are congenital in origin. | A characteristic congenital malformation pattern is not described. | High |
| Abnormal acid processing | Not primarily described as an organic aciduria. | An abnormal metabolite may suggest impaired acid processing but is not itself a diagnosis. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Developmental delay with variable congenital features from birth
This pattern fits the supplied chromosomal-disorder description better than an isolated metabolic finding.
Moderate
Genetic testing suggests terminal chromosome 6 material loss
A confirmed relevant deletion supports the chromosomal condition when clinically correlated.
High
Counseling centers on a lifelong congenital genetic syndrome
The supplied category is genetic and congenital rather than primarily metabolic.
Moderate
Choose 2 Hydroxyphenylacetic Aciduria C5937087 when
Infancy evaluation finds 2-hydroxyphenylacetic aciduria
The named biochemical abnormality directs attention to a metabolic disorder, pending specialist confirmation.
Moderate
Neurological concerns occur without a described congenital syndrome
The source links possible neurological issues to abnormal acid processing.
Low
Management discussion involves diet modification and supportive care
Those approaches are described for the metabolic condition, not as chromosome-specific treatment.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 2 Hydroxyphenylacetic Aciduria C5937087 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion at the terminal region of chromosome 6. | No characteristic chromosomal deletion is described. | A genetic result requires clinical correlation and does not exclude a separate metabolic issue. |
| Urine organic acid analysis | No characteristic metabolite pattern is established in the supplied data. | May show 2-hydroxyphenylacetic aciduria; no numeric cutoff is supplied. | An abnormal result is not a definitive diagnosis and needs metabolic specialist interpretation. |
| Specialist clinical assessment | Genetics-focused assessment of development and variable physical findings. | Metabolic assessment of neurological status, diet, and supportive needs. | Testing choice should follow the dominant clinical clues rather than either label alone. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Extent of deletion, developmental needs, and associated physical findings may matter.
2 Hydroxyphenylacetic Aciduria C5937087
- Outcome
- Described as moderate and chronic, with outcome variability not quantified.
- Factors
- Neurological involvement, age at recognition, and response to supportive or dietary care may matter.
Time frame: Both may require long-term follow-up from infancy or birth; exact course is not established.
Prognosis should be individualized by clinicians; no mortality or prevalence figures are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopmental impact | Developmental delay is described; exact range is not established. Neurological issues may occur, but frequency and severity are not established. Neither source provides definitive complication rates. |
| Physical or congenital complications | Variable physical features may create individualized medical needs. No specific congenital complication pattern is supplied. Avoid assuming a uniform malformation profile. |
| Treatment-related burden | Supportive and developmental care needs may be substantial. Diet modification and supportive care may add monitoring needs. No doses, restrictions, or outcome claims are established here. |
Patient education highlights
- HighDiagnosis versus test result
A chromosomal finding or aciduria result needs clinician interpretation and does not by itself prove every associated problem.
- HighDifferent causes
One condition is a congenital genetic deletion; the other is a rare metabolic disorder.
- MediumCare planning
Ask specialists which developmental, nutritional, and supportive evaluations are appropriate for the individual.